The Principals

The founders of Secretory IgA, Inc have varied academic and industrial backgrounds that together position them ideally to accomplish this mission.

Michael R. Simon, M.D., President

Michael R. Simon received his M.D. from New York University School of Medicine. He is Clinical Professor Emeritus in the Departments of Internal Medicine and Pediatrics, Wayne State University School of Medicine, Detroit, MI. Dr. Simon is a clinical immunologist who is the founder of Secretory IgA , Inc. and has particular expertise in the immunology and clinical manifestations of inflammatory disease. He is the author and owner of the relevant intellectual property.

R. Scott Olson, Chief Executive Officer

R. Scott Olson, MBA, is the Company’s CEO. Following a career in finance, Mr. Olson began consulting to life science companies in 1999. He earned an MBA from the Ross School of Business at the University of Michigan. He has founded or been an executive in seven companies, including Unitech Pharmaceuticals, a therapeutic company acquired by GeneBlue Corporation. He has consulted hundreds of emerging companies in strategic and financial matters.

Stephen C. Brown, Ph.D., Chief Scientific Officer

Stephen C. Brown received his Ph.D. from the University of California, San Francisco. He was previously a Research Fellow and Director of Chemistry at Esperion Therapeutics, Inc. Dr. Brown was closely involved in the ETC-216 and ETC-642 projects which both reached Phase II clinical evaluation trials. These projects were purchased by Pfizer, Inc. in 2004 and are continuing through clinical development. He has extensive prior experience in protein chemistry, protein production and purification, and protein characterization using advanced analytical techniques.

Richard W. Frazee, Ph.D., Senior Scientist

Richard W. Frazee received his Ph.D. from the Department of Biochemistry at the University of Minnesota, Minneapolis, where he worked on the purification and characterization of metalloproteins. He was an NSF Postdoctoral Fellow at the Johns Hopkins University and a NSF funded Assistant Professor at the University of Michigan-Flint and at Rowan University in New Jersey where he directed research programs in the molecular biology of transcriptional regulation in developmental biology. More recently he was a senior research fellow at the University of Michigan where he worked on the biochemical mechanism of drug interaction with the mitochondrial ATPase stator. Dr. Frazee brings a breadth of experience in protein biochemistry including production, purification, biophysical characterization, immunodetection, DNA cloning, and site directed mutagenesis.